Dermatol. praxi. 2011;5(2):64-68 [Med. praxi. 2011;8(2):73-76]

Etiology, clinical features and treatment of onychomycosis

doc. MUDr. Ivana Kuklová, CSc.
Centrum pro léčbu dermatomykóz, Dermatovenerologická klinika 1. LF UK a VFN, Praha

Onychomycosis is an infection of the nail apparatus by microscopic fungi that include dermatophytes, yeasts (mainly Candida species) and nondermatophyte moulds. Dermatophyte infection, mostly due to Trichophyton rubrum, is the cause in over 90 % of cases. The distribution of different pathogens depends on various factors such as climate, geography, migration, diabetes, acquired immunodeficiency syndrome and peripheral arterial disease. Laboratory diagnosis consists of microscopy to visualize fungal elements (mycelia and spores) in the nail sample and culture to identify the species concerned. Systemic therapy is almost always more successful than topical treatment, which should only be used in very early DLSO and SWO, or when systemic therapy is contraindicated.

Keywords: onychomycosis, clinical picture, therapy

Published: June 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kuklová I. Etiology, clinical features and treatment of onychomycosis. Dermatol. praxi. 2011;5(2):64-68.
Download citation

References

  1. Baran R, Hay RJ, Garduno JI. Review of antifungal therapy, part II: treatment rationale, including specific patient populations. J Dermatolog Treat 2008; 19(3): 168-175. Go to original source... Go to PubMed...
  2. Borelli C, Schaller M, Niewerth M, et al. Modes of action of the new arylguanidine abafungin beyond interference with ergosterol biosynthesis and in vitro activity against medically important fungi. Chemotherapy. 2008; 54: 245-259. Go to original source... Go to PubMed...
  3. Elewski B. Diagnostic techniques for confirming onychomycosis. J Am Acad Dermatol 1996; 35(2): 6-9. Go to original source... Go to PubMed...
  4. Gupta AK, Lambert J, Revuz J, Shear N. Update on the safety of itraconazole pulse therapy in onychomycosis and dermatomycoses. Eur J Dermatol. 2001; 11(1): 6-10.
  5. Gupta AK, Shear NH. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis. Drug Saf 2000; 22(1): 33-52. Go to original source... Go to PubMed...
  6. Jedličková A, Mašata J, Skořepová M. Lokální mykózy. Praha: Jessenius Maxdorf, 2008.
  7. Kuklová I, Kučerová H. Fungal infections in Prague, Czech Republic, between 1987 and 1998. Mycoses 2001; 44: 493-496. Go to original source... Go to PubMed...
  8. Litvik R. Lokální a systémová léčba onychomykóz - doporučení pro praxi. Remedia on line, 1/2009.
  9. Roberts DT, Taylor WD, Boyle J. Guidelines for treatment of onychomycosis. Br J Dermatol 2003; 148: 402-410. Go to original source... Go to PubMed...
  10. Scher RK, Baran R. Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol 2003; 149(Suppl. s 65): 5-9. Go to original source... Go to PubMed...
  11. Smijs TG, Pavel S. The susceptibility of dermatophytes to photodynamic treatment with special focus on Trichophyton rubrum. Photochem Photobiol 2011; 87(1): 2-13. Go to original source... Go to PubMed...




Dermatology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.